The Evolving CGM Landscape and GS1’s Strategic Expansion in Europe

  1. CGM Industry Trends: From Diabetes Care to Holistic Health Management
The global Continuous Glucose Monitoring (CGM) market is undergoing a paradigm shift. While early adoption focused on Type 1 diabetes, advancements in non-invasive technology and cost reduction are driving demand among Type 2 diabetics and even non-diabetic populations812. Key trends include:
  • Expansion to Non-Diabetic Users: Devices like Abbott’s Lingo target metabolic health optimization, offering insights into glucose responses to diet, exercise, and sleep.
  • OTC Accessibility: Over-the-counter CGM products are emerging, empowering users to monitor glucose without prescriptions.
The GS1 CGM, developed by SIBIONICS, aligns with these trends. Its non-invasive sensor and long-term wearability make it ideal for both diabetic management and preventive health monitoring16.
  1. Europe’s CGM Market: Growth Drivers and GS1’s Entry
Europe represents a high-growth CGM market, driven by rising diabetes prevalence and demand for non-invasive solutions. For instance, Saudi Arabia’s diabetic population exceeds 4.2 million, creating urgent needs for advanced glucose management tools.
GS1’s Strategic Success in the Middle East: SIBIONICS partnered with ProMedEx to launch GS1 in Saudi Arabia, addressing local healthcare gaps through:
  • Real-Time Data Integration: Enables remote monitoring for physicians, critical in regions with limited medical infrastructure.
  • Cost-Effective Design: Eliminates recurring expenses for test strips, reducing long-term patient costs.
This expansion mirrors Europe’s demand for innovative CGM solutions. Analysts predict the European CGM market will grow at a CAGR of 12.3% through 2027, with non-invasive devices like GS1 leading adoption.
  1. AGP Reports: Bridging Data and Clinical Decisions
The Ambulatory Glucose Profile (AGP) is a cornerstone of CGM utility. For GS1 users, AGP metrics like Time-in-Range (TIR) and glycemic variability provide actionable insights:
  • TIR Optimization: Studies show 86.8% TIR in Type 2 diabetics using CGM, significantly reducing complication risks.
  • Personalized Interventions: Physicians leverage AGP data to tailor insulin dosing and lifestyle recommendations
By integrating AGP analytics, GS1 enhances both patient self-management and clinical outcomes, positioning it as a leader in data-driven diabetes care

 


SIBIONICS GS1 CGM-sustav za kontinuirano praćenje glukoze SIBIONICS GS1 CGM 14-dnevni kontinuirani sustav za praćenje glukoze Posebne ponude masovne kupnje - SIBIONICS GS1 CGM kontinuirani sustav za praćenje glukoze

Potpuno novo

SIBIONICS GS1 sustav kontinuiranog praćenja glukoze (CGM).

Vrlo precizna očitanja senzora
14-dnevna kontinuirana glukoza
Praćenje Bez kalibracije
Nema skeniranja
AGP izvješća koja se mogu izvoziti
IP28 vodootporan
Prilagodljivi alarm za glukozu
Aplikacija prilagođena korisniku
Podaci o glukozi u stvarnom vremenu koji se mogu dijeliti

Trgovina GS1